In a new study, researchers examined the Renal Activity Index for Lupus (RAIL) diagnostic tool to assess its success for ...

Ventus Therapeutics, a clinical-stage biopharmaceutical company advancing multiple small-molecule programs for immunological, ...

The decision is based on outcomes from the Phase II NOBILITY and Phase III REGENCY trials.

Dermatologists long reluctant to tackle cutaneous lupus erythematosus may be more open to treating patients with approvals ...

In November 2024, the American College of Rheumatology (ACR) released a summary of their new guidelines for the screening, treatment, and management of lupus nephritis. What is important for a patient ...

The younger that someone is when certain illnesses hit, especially before puberty, the more severe symptoms may be. And while ...

A regulatory decision is expected by October 2025. The Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for obinutuzumab (Gazyva ®) for the ...

What are called autoimmune diseases can affect just about every part of the body — and tens of millions of people. While most ...

Learn how MDS/CMML-associated lupus differs from classic lupus and why clone-directed therapies may offer better outcomes. Find out more.